Current and future pharmacological therapies for NAFLD/NASH
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which a...
Saved in:
| Published in | Journal of gastroenterology Vol. 53; no. 3; pp. 362 - 376 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Tokyo
Springer Japan
01.03.2018
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0944-1174 1435-5922 1435-5922 |
| DOI | 10.1007/s00535-017-1415-1 |
Cover
| Abstract | Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. Innovative NASH therapies include four main pathways. The first approach is targeting hepatic fat accumulation. Medications in this approach include modulation of peroxisome proliferator-activator receptors (e.g., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. A second target is oxidative stress, inflammation, and apoptosis. This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target is intestinal microbiomes and metabolic endotoxemia. Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and solithromycin (macrolide antibiotics). The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortality in NASH. Antifibrotic agents are a cysteine–cysteine motif chemokine receptor-2/5 antagonist (cenicriviroc; CVC) and galectin 3 antagonist. Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases. |
|---|---|
| AbstractList | Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. Innovative NASH therapies include four main pathways. The first approach is targeting hepatic fat accumulation. Medications in this approach include modulation of peroxisome proliferator-activator receptors (e.g., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. A second target is oxidative stress, inflammation, and apoptosis. This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target is intestinal microbiomes and metabolic endotoxemia. Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and solithromycin (macrolide antibiotics). The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortality in NASH. Antifibrotic agents are a cysteine–cysteine motif chemokine receptor-2/5 antagonist (cenicriviroc; CVC) and galectin 3 antagonist. Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases. Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. Innovative NASH therapies include four main pathways. The first approach is targeting hepatic fat accumulation. Medications in this approach include modulation of peroxisome proliferator-activator receptors (e.g., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. A second target is oxidative stress, inflammation, and apoptosis. This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target is intestinal microbiomes and metabolic endotoxemia. Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and solithromycin (macrolide antibiotics). The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortality in NASH. Antifibrotic agents are a cysteine-cysteine motif chemokine receptor-2/5 antagonist (cenicriviroc; CVC) and galectin 3 antagonist. Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases.Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which are currently approved for use in diabetes, have shown early efficacy in NASH, and also have beneficial cardiovascular or renal effects. Innovative NASH therapies include four main pathways. The first approach is targeting hepatic fat accumulation. Medications in this approach include modulation of peroxisome proliferator-activator receptors (e.g., pemafibrate, elafibranor), medications targeting farnesoid X receptor axis [obeticholic acid; OCA)], inhibitors of de novo lipogenesis (aramchol, ACC inhibitor), and fibroblast growth factor-21 analogues. A second target is oxidative stress, inflammation, and apoptosis. This class of drug includes apoptosis signaling kinase 1 (ASK1) inhibitor and emricasan (an irreversible caspase inhibitor). A third target is intestinal microbiomes and metabolic endotoxemia. Several agents are in ongoing trials, including IMMe124, TLR4 antagonist, and solithromycin (macrolide antibiotics). The final target is hepatic fibrosis, which is strongly associated with all-cause or liver-related mortality in NASH. Antifibrotic agents are a cysteine-cysteine motif chemokine receptor-2/5 antagonist (cenicriviroc; CVC) and galectin 3 antagonist. Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH. Within the next few years, the availability of therapeutic options for NASH will hopefully curb the rising trend of NASH-related diseases. |
| Audience | Academic |
| Author | Yoneda, Masashi Sumida, Yoshio |
| Author_xml | – sequence: 1 givenname: Yoshio surname: Sumida fullname: Sumida, Yoshio email: sumida.yoshio.500@mail.aichi-med-u.ac.jp organization: Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University – sequence: 2 givenname: Masashi surname: Yoneda fullname: Yoneda, Masashi organization: Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29247356$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt9rFDEQx4NU7LX6B_giC774sm0mPzYJgnCc1gpHfVCfQzab3KXsbs5kt-B_b86rtS0q8xBIPt-ZzMz3BB2NcXQIvQR8BhiL84wxp7zGIGpgwGt4ghbAyg1XhByhBVaM1QCCHaOTnK8xBoq5fIaOiSJMUN4s0NvVnJIbp8qMXeXnaU6u2m1NGoyNfdwEa_pq2rpkdsHlysdUXS0v1u_Pr5ZfLp-jp9702b24PU_Rt4sPX1eX9frzx0-r5bq2DRFTzYVpuLTWKWIIcGJbyam3IBzFrXeAOwYtpaAsqAZLLzojSdO2SnlFXYlT9O6Qdze3g-ts-W4yvd6lMJj0Q0cT9MOXMWz1Jt5oLpko3ZcEb24TpPh9dnnSQ8jW9b0ZXZyzBiWEkIxIVdDXj9DrOKextPeL4pg0mP2hNqZ3Oow-lrp2n1QvBTAuKVVNoc7-QpXo3BBsWaUP5f6B4NX9Ru86_L2uAsABsCnmnJy_QwDrvSX0wRK6WELvLaGhaMQjjQ2TmULczyr0_1WSgzKXKuPGpXuz-KfoJweSxu4 |
| CitedBy_id | crossref_primary_10_1021_acsomega_0c00529 crossref_primary_10_1007_s10522_023_10023_4 crossref_primary_10_3389_fphar_2021_704112 crossref_primary_10_1038_s41598_023_41160_y crossref_primary_10_3390_ijms231911030 crossref_primary_10_3389_fchem_2022_888587 crossref_primary_10_4292_wjgpt_v15_i6_97381 crossref_primary_10_1053_j_gastro_2020_03_010 crossref_primary_10_1080_13813455_2021_1939387 crossref_primary_10_1016_j_diabet_2019_01_008 crossref_primary_10_3389_fimmu_2022_954869 crossref_primary_10_3389_fgstr_2024_1534431 crossref_primary_10_1021_acs_jafc_8b01831 crossref_primary_10_2147_CPAA_S409786 crossref_primary_10_1039_D0FO02123G crossref_primary_10_7759_cureus_50159 crossref_primary_10_2169_naika_109_64 crossref_primary_10_1016_j_apsb_2021_03_018 crossref_primary_10_1055_a_1301_2378 crossref_primary_10_1016_j_jlr_2025_100757 crossref_primary_10_1016_j_ctim_2021_102699 crossref_primary_10_1038_s12276_022_00851_8 crossref_primary_10_1155_2021_3715026 crossref_primary_10_1016_j_addr_2019_11_001 crossref_primary_10_1016_j_nut_2020_111080 crossref_primary_10_1016_j_jconrel_2022_01_038 crossref_primary_10_2147_DMSO_S449494 crossref_primary_10_1038_s41467_020_16991_2 crossref_primary_10_1111_hepr_13236 crossref_primary_10_1016_j_gendis_2021_12_011 crossref_primary_10_1002_2211_5463_12734 crossref_primary_10_1038_s41575_020_0266_z crossref_primary_10_3390_ijms19072034 crossref_primary_10_1016_j_ejmech_2020_112311 crossref_primary_10_1016_j_jep_2022_114999 crossref_primary_10_1093_jpp_rgad031 crossref_primary_10_1152_ajpgi_00397_2020 crossref_primary_10_20517_mtod_2024_44 crossref_primary_10_3390_cimb46070376 crossref_primary_10_1016_j_bbrc_2023_05_027 crossref_primary_10_1002_jat_4410 crossref_primary_10_1111_cpr_13796 crossref_primary_10_1016_j_phymed_2024_156317 crossref_primary_10_1016_j_cld_2018_09_008 crossref_primary_10_1016_j_jep_2024_118354 crossref_primary_10_1016_j_soard_2020_01_028 crossref_primary_10_1038_s43587_024_00652_w crossref_primary_10_3892_mmr_2019_10139 crossref_primary_10_3390_nu11112834 crossref_primary_10_3748_wjg_v24_i25_2661 crossref_primary_10_1186_s12876_022_02410_x crossref_primary_10_12688_f1000research_14841_1 crossref_primary_10_3389_fphar_2019_01235 crossref_primary_10_3390_ijms21124337 crossref_primary_10_1080_17474124_2018_1533117 crossref_primary_10_1016_j_trsl_2024_06_002 crossref_primary_10_1021_acs_jcim_9b00838 crossref_primary_10_3390_ijms22094495 crossref_primary_10_1002_jgh3_12384 crossref_primary_10_3389_fcell_2021_717610 crossref_primary_10_1177_09603271211038741 crossref_primary_10_1515_biol_2022_0583 crossref_primary_10_3389_fendo_2020_597583 crossref_primary_10_1002_mnfr_202200447 crossref_primary_10_1042_CS20220572 crossref_primary_10_1111_bph_14938 crossref_primary_10_1155_2021_5522755 crossref_primary_10_3390_ijms19072130 crossref_primary_10_1016_j_lfs_2022_121185 crossref_primary_10_1248_bpb_b20_00358 crossref_primary_10_1021_acs_jmedchem_0c00640 crossref_primary_10_3389_fimmu_2024_1439971 crossref_primary_10_3390_biology11081237 crossref_primary_10_3390_nu15010178 crossref_primary_10_4103_JOD_JOD_81_20 crossref_primary_10_1155_2020_4020249 crossref_primary_10_2147_DMSO_S380053 crossref_primary_10_1002_jgh3_12367 crossref_primary_10_1016_j_jbc_2021_101331 crossref_primary_10_1097_MD_0000000000020699 crossref_primary_10_12677_acm_2025_153639 crossref_primary_10_1016_j_jlr_2024_100695 crossref_primary_10_1002_hep_31233 crossref_primary_10_3389_fcvm_2021_742382 crossref_primary_10_1016_j_phymed_2021_153498 crossref_primary_10_33160_yam_2020_08_009 crossref_primary_10_1080_13813455_2022_2102654 crossref_primary_10_2147_DDDT_S307257 crossref_primary_10_3390_ph13090222 crossref_primary_10_3390_jcm8122175 crossref_primary_10_1108_NFS_04_2018_0119 crossref_primary_10_1016_j_bcp_2024_116240 crossref_primary_10_1038_s41366_018_0151_9 crossref_primary_10_1002_jgh3_13012 crossref_primary_10_3390_ijms232213967 crossref_primary_10_1016_j_phrs_2020_104679 crossref_primary_10_1016_j_jlr_2023_100382 crossref_primary_10_14218_JCTH_2021_00289 crossref_primary_10_1055_s_0041_1739455 crossref_primary_10_1186_s12876_022_02290_1 crossref_primary_10_1155_2020_8829346 crossref_primary_10_1016_j_bbrc_2022_03_055 crossref_primary_10_1186_s12951_025_03228_x crossref_primary_10_1016_j_carbpol_2024_122139 crossref_primary_10_1016_j_ejpb_2022_11_025 crossref_primary_10_1038_s41418_023_01183_4 crossref_primary_10_1016_j_xcrm_2021_100437 crossref_primary_10_3390_nu12010184 crossref_primary_10_3390_jcm10081569 crossref_primary_10_1007_s10565_020_09544_2 crossref_primary_10_1080_13813455_2020_1789881 crossref_primary_10_2147_DDDT_S384884 crossref_primary_10_1016_j_ejmech_2024_116723 crossref_primary_10_1097_QCO_0000000000000759 crossref_primary_10_1016_j_bbalip_2024_159497 crossref_primary_10_1016_j_apsb_2021_08_003 crossref_primary_10_1080_07391102_2023_2256867 crossref_primary_10_3389_fimmu_2019_02893 crossref_primary_10_2139_ssrn_4179070 crossref_primary_10_1016_j_abb_2025_110313 crossref_primary_10_3350_cmh_2023_0315 crossref_primary_10_3390_ijms23147841 crossref_primary_10_1016_j_apsb_2019_11_017 crossref_primary_10_3390_antiox13040485 crossref_primary_10_1042_BSR20221375 crossref_primary_10_1038_s41598_024_65239_2 crossref_primary_10_2337_dc18_0588 crossref_primary_10_1016_j_heliyon_2023_e22464 crossref_primary_10_3389_fphar_2021_742465 crossref_primary_10_1016_j_nut_2020_110938 crossref_primary_10_1016_j_isci_2022_105905 crossref_primary_10_3390_ijms242417147 crossref_primary_10_1038_s41598_024_70242_8 crossref_primary_10_3389_fendo_2022_1046130 crossref_primary_10_1007_s00210_019_01705_3 crossref_primary_10_3390_cells9040964 crossref_primary_10_1016_j_ajpc_2024_100638 crossref_primary_10_1021_acs_jafc_2c07702 crossref_primary_10_1289_EHP11600 crossref_primary_10_1161_ATVBAHA_118_312028 crossref_primary_10_1002_hep4_1474 crossref_primary_10_3390_life12030355 crossref_primary_10_3390_biomedicines8090350 crossref_primary_10_1111_cbdd_14021 crossref_primary_10_1080_14656566_2018_1531126 crossref_primary_10_3390_jcm11030753 crossref_primary_10_3390_cells11182854 crossref_primary_10_1016_j_scispo_2021_12_008 crossref_primary_10_1007_s00210_024_03204_6 crossref_primary_10_1038_s41522_023_00399_z crossref_primary_10_3748_wjg_v30_i29_3456 crossref_primary_10_1016_j_phrs_2025_107706 crossref_primary_10_1021_acs_biomac_1c01360 crossref_primary_10_3390_medicina56100544 crossref_primary_10_1371_journal_pone_0246837 crossref_primary_10_3389_fimmu_2024_1336493 crossref_primary_10_3390_ph16111601 crossref_primary_10_1089_dia_2019_0158 crossref_primary_10_4068_cmj_2024_60_1_13 crossref_primary_10_1002_jbt_23566 crossref_primary_10_1016_j_jep_2019_03_006 crossref_primary_10_1016_S2468_1253_22_00317_X crossref_primary_10_3389_fendo_2022_792439 crossref_primary_10_3390_ijms241411313 crossref_primary_10_1016_j_biopha_2022_113764 crossref_primary_10_1016_j_ijbiomac_2024_134363 crossref_primary_10_5551_jat_63159 crossref_primary_10_1186_s12967_023_04627_0 crossref_primary_10_3390_pharmaceutics15082163 crossref_primary_10_62347_MKIV1986 crossref_primary_10_3389_fphar_2020_00185 crossref_primary_10_1002_pep2_24221 crossref_primary_10_1038_s41598_018_31708_8 crossref_primary_10_1016_j_chmed_2021_05_001 crossref_primary_10_2147_DDDT_S386982 crossref_primary_10_3390_antiox10122031 crossref_primary_10_3390_ncrna6030034 crossref_primary_10_1002_hep_32045 crossref_primary_10_3390_foods10061346 crossref_primary_10_1016_j_health_2023_100160 crossref_primary_10_1016_j_bbrc_2022_01_059 crossref_primary_10_3164_jcbn_21_69 crossref_primary_10_1038_s42003_023_04710_8 crossref_primary_10_3389_fphar_2021_826628 crossref_primary_10_1111_ctr_13700 crossref_primary_10_1186_s10020_021_00428_7 crossref_primary_10_1002_edm2_460 crossref_primary_10_3389_fnut_2023_1086477 crossref_primary_10_1016_j_aohep_2019_07_013 crossref_primary_10_1016_j_biomaterials_2021_120904 crossref_primary_10_20517_2394_5079_2023_134 crossref_primary_10_3389_fmed_2023_1120621 crossref_primary_10_1016_j_jceh_2023_07_415 crossref_primary_10_3390_biomedicines11020468 crossref_primary_10_1038_s41467_023_39028_w crossref_primary_10_1097_HC9_0000000000000310 crossref_primary_10_1016_j_drudis_2022_05_007 crossref_primary_10_1038_s41598_020_70689_5 crossref_primary_10_1210_clinem_dgad249 crossref_primary_10_1016_j_lfs_2020_118196 crossref_primary_10_1016_j_rx_2025_02_005 crossref_primary_10_33326_26176068_2021_4_1259 crossref_primary_10_1007_s40005_024_00681_y crossref_primary_10_1016_j_biopha_2018_04_143 crossref_primary_10_1097_MD_0000000000026835 crossref_primary_10_1158_1940_6207_CAPR_20_0220 crossref_primary_10_1016_j_phrs_2020_104984 crossref_primary_10_1155_2021_6659445 crossref_primary_10_1002_cyto_b_21790 crossref_primary_10_3390_ijms222413219 crossref_primary_10_1038_s41587_021_00946_z crossref_primary_10_4239_wjd_v12_i1_84 crossref_primary_10_1016_j_metabol_2019_04_008 crossref_primary_10_5009_gnl220545 crossref_primary_10_1016_j_ejphar_2022_174841 crossref_primary_10_3389_fmed_2025_1509947 crossref_primary_10_3389_fmed_2024_1420281 crossref_primary_10_2174_0113895575306598240503054317 crossref_primary_10_1016_j_bbrc_2022_01_086 crossref_primary_10_1142_S0192415X19500642 crossref_primary_10_4274_meandros_galenos_2021_32932 crossref_primary_10_3390_jcm12175597 crossref_primary_10_1016_j_lfs_2024_123362 crossref_primary_10_3389_fnut_2023_1327814 crossref_primary_10_1097_CRD_0000000000000379 crossref_primary_10_3390_nu14214673 crossref_primary_10_1007_s11883_022_01028_4 crossref_primary_10_1186_s40360_024_00800_3 crossref_primary_10_14309_ajg_0000000000000845 crossref_primary_10_1038_s41598_021_88025_w crossref_primary_10_5650_jos_ess21228 crossref_primary_10_3390_cancers15010023 crossref_primary_10_1016_j_bcp_2024_116073 crossref_primary_10_3390_nu14163262 crossref_primary_10_1002_ptr_7344 crossref_primary_10_1186_s13098_022_00885_y crossref_primary_10_3390_nu14122509 crossref_primary_10_3390_antiox8080276 crossref_primary_10_1002_hep_32068 crossref_primary_10_3920_CEP210033 crossref_primary_10_3390_biom13101506 crossref_primary_10_1038_s41429_022_00522_w crossref_primary_10_1155_2022_8560831 crossref_primary_10_1016_j_ejphar_2023_175834 crossref_primary_10_1177_1934578X241245020 crossref_primary_10_3389_fphar_2023_1152042 crossref_primary_10_3390_biomedicines11082199 crossref_primary_10_1016_j_tem_2019_08_008 crossref_primary_10_1016_j_carbpol_2022_119388 crossref_primary_10_3892_ijmm_2024_5412 crossref_primary_10_1002_jsfa_12854 crossref_primary_10_1016_j_freeradbiomed_2021_10_017 crossref_primary_10_1371_journal_pone_0219412 crossref_primary_10_2147_JIR_S413565 crossref_primary_10_1016_j_metabol_2022_155264 crossref_primary_10_3389_fendo_2022_899731 crossref_primary_10_3390_medsci9020039 crossref_primary_10_3390_microorganisms13030675 crossref_primary_10_1016_j_freeradbiomed_2021_09_001 crossref_primary_10_1007_s00125_018_4678_z crossref_primary_10_1016_j_livres_2023_08_005 crossref_primary_10_3390_ph11040104 crossref_primary_10_29328_journal_acgh_1001030 crossref_primary_10_3390_medicina55050166 crossref_primary_10_1093_jb_mvaa145 crossref_primary_10_3390_biomedicines9030326 crossref_primary_10_3389_fphar_2022_869446 crossref_primary_10_1007_s00535_022_01929_w crossref_primary_10_1016_j_biopha_2020_110076 crossref_primary_10_1016_j_ijbiomac_2018_09_151 crossref_primary_10_2174_0929867329666221007115809 crossref_primary_10_3390_ijms19071893 crossref_primary_10_1007_s40618_023_02216_y crossref_primary_10_1155_2023_7277060 crossref_primary_10_3390_biomedicines9111647 crossref_primary_10_3389_fcvm_2024_1469492 crossref_primary_10_1016_j_jcmgh_2023_09_001 crossref_primary_10_1039_C8FO01452C crossref_primary_10_3389_fimmu_2022_893617 crossref_primary_10_1177_20420188211020664 crossref_primary_10_3390_ijms20205037 crossref_primary_10_1016_j_jhepr_2019_08_002 crossref_primary_10_1016_j_phyplu_2021_100055 crossref_primary_10_1021_acs_jafc_0c00280 crossref_primary_10_3389_fendo_2024_1431652 crossref_primary_10_1186_s43066_021_00134_3 crossref_primary_10_3390_ijms20163987 crossref_primary_10_3390_diseases6040086 crossref_primary_10_1007_s11033_024_10088_5 crossref_primary_10_3390_cells10102772 crossref_primary_10_1155_2021_6610124 crossref_primary_10_3390_life11020143 crossref_primary_10_1055_a_1273_3159 crossref_primary_10_1016_j_medj_2024_03_013 crossref_primary_10_1186_s12944_024_02108_x crossref_primary_10_1016_j_bioorg_2020_103803 crossref_primary_10_3390_livers3040038 crossref_primary_10_3389_fimmu_2022_857892 crossref_primary_10_1016_j_lfs_2022_120634 crossref_primary_10_3390_nu12072141 crossref_primary_10_1080_14656566_2019_1702967 crossref_primary_10_1186_s13098_024_01526_2 crossref_primary_10_3389_fmmed_2023_1283170 crossref_primary_10_3390_nu13082830 crossref_primary_10_2174_1381612825666191026113119 crossref_primary_10_1038_s41598_020_58030_6 crossref_primary_10_1186_s10020_024_00945_1 crossref_primary_10_3748_wjg_v26_i21_2740 crossref_primary_10_1016_j_phrs_2022_106621 crossref_primary_10_3389_fmed_2021_615978 crossref_primary_10_1080_17474124_2020_1748498 crossref_primary_10_2139_ssrn_3865274 crossref_primary_10_12701_yujm_2019_00171 crossref_primary_10_1038_s41418_020_0491_6 crossref_primary_10_1371_journal_pone_0244762 crossref_primary_10_1016_S2468_1253_20_30186_2 crossref_primary_10_3390_cells11233870 crossref_primary_10_1016_j_biopha_2024_116405 crossref_primary_10_1016_j_biopha_2024_116519 crossref_primary_10_1021_acs_jafc_3c01067 crossref_primary_10_3399_bjgp18X699377 crossref_primary_10_1210_er_2018_00064 crossref_primary_10_3390_ph15050578 crossref_primary_10_1556_1647_2020_00006 crossref_primary_10_3389_fmicb_2020_555293 crossref_primary_10_1016_j_yexcr_2020_111949 crossref_primary_10_3164_jcbn_20_129 crossref_primary_10_1016_j_cmet_2020_11_010 crossref_primary_10_3390_jcm12206561 crossref_primary_10_3389_fnut_2023_1107551 crossref_primary_10_1016_j_cct_2020_106174 crossref_primary_10_1371_journal_pone_0232886 crossref_primary_10_1111_jcmm_15286 crossref_primary_10_1371_journal_pone_0250261 crossref_primary_10_1016_j_bbrc_2021_04_012 crossref_primary_10_1080_14728214_2020_1796968 crossref_primary_10_1002_ptr_7762 crossref_primary_10_3390_cells8050417 crossref_primary_10_1007_s12072_024_10698_y crossref_primary_10_1016_j_ooc_2021_100010 crossref_primary_10_1002_jcp_28821 crossref_primary_10_1007_s12325_019_00960_3 crossref_primary_10_1155_2021_3654660 crossref_primary_10_1016_j_ajpath_2019_08_005 crossref_primary_10_1371_journal_pone_0239393 crossref_primary_10_3389_fphar_2022_1016745 crossref_primary_10_1016_j_clnu_2019_10_011 crossref_primary_10_1016_j_jff_2023_105661 crossref_primary_10_1007_s11892_019_1244_0 crossref_primary_10_1111_dom_15548 crossref_primary_10_3390_cells10123306 crossref_primary_10_1507_endocrj_EJ24_0005 crossref_primary_10_3390_biomedicines13030644 crossref_primary_10_1111_1750_3841_15482 crossref_primary_10_1556_650_2022_32480 crossref_primary_10_1038_s41575_020_00386_1 crossref_primary_10_3390_biom15040469 crossref_primary_10_1155_2022_5805398 crossref_primary_10_1186_s13287_022_03201_7 crossref_primary_10_1111_jgh_15974 crossref_primary_10_1016_j_ijbiomac_2025_140444 crossref_primary_10_3390_ijms25115571 crossref_primary_10_3748_wjg_v25_i2_163 crossref_primary_10_1096_fj_202201972RR crossref_primary_10_3390_nu14224750 crossref_primary_10_52711_0974_360X_2025_00036 crossref_primary_10_3390_biomedicines9040353 crossref_primary_10_1016_j_phymed_2023_155005 crossref_primary_10_3389_fendo_2018_00539 crossref_primary_10_3389_fendo_2021_648844 crossref_primary_10_1186_s13098_022_00976_w crossref_primary_10_1371_journal_pone_0228011 crossref_primary_10_1016_j_advms_2024_09_001 crossref_primary_10_1002_hep_30603 crossref_primary_10_3390_metabo14010012 crossref_primary_10_2174_1568026623666230714113808 crossref_primary_10_3390_molecules28041734 crossref_primary_10_3390_ijms23052668 crossref_primary_10_3390_pharmaceutics11120676 crossref_primary_10_1002_hep4_1331 crossref_primary_10_1016_j_phrs_2022_106426 crossref_primary_10_3803_EnM_2020_35_2_329 crossref_primary_10_1007_s00210_024_03539_0 crossref_primary_10_1142_S0192415X24500137 crossref_primary_10_1097_HJH_0000000000002279 crossref_primary_10_1016_j_ejmech_2021_114089 crossref_primary_10_1016_j_lfs_2024_122642 crossref_primary_10_3390_nu15204375 crossref_primary_10_3389_fphar_2020_554961 crossref_primary_10_1016_j_biopha_2023_114300 crossref_primary_10_31146_1682_8658_ecg_170_10_18_25 crossref_primary_10_2147_JIR_S344071 crossref_primary_10_2478_orvtudert_2022_0006 crossref_primary_10_1002_2211_5463_12598 crossref_primary_10_1038_s41401_021_00849_4 crossref_primary_10_1016_j_heliyon_2024_e35498 crossref_primary_10_3390_foods10081719 crossref_primary_10_3390_nu13114014 crossref_primary_10_1055_a_1202_0818 crossref_primary_10_1007_s11901_020_00540_y crossref_primary_10_2478_abm_2022_0001 crossref_primary_10_1002_ctd2_98 crossref_primary_10_1016_j_pharma_2024_02_005 crossref_primary_10_1002_cld_709 crossref_primary_10_3390_medsci6020047 crossref_primary_10_1038_s41598_020_75805_z crossref_primary_10_3389_fmed_2020_00361 crossref_primary_10_1038_s41598_022_15840_0 crossref_primary_10_1111_obr_12820 crossref_primary_10_1016_j_ejmech_2023_115992 crossref_primary_10_1155_2020_9734560 crossref_primary_10_1097_MCO_0000000000000539 crossref_primary_10_31146_1682_8658_ecg_194_10_82_90 crossref_primary_10_1016_j_jacc_2018_11_050 crossref_primary_10_1186_s12889_020_09249_5 crossref_primary_10_1016_j_jceh_2024_101365 crossref_primary_10_1186_s11658_021_00254_z crossref_primary_10_1007_s11938_020_00290_2 crossref_primary_10_1155_2020_4503253 crossref_primary_10_1186_s12889_024_20851_9 crossref_primary_10_3748_wjg_v26_i16_1901 crossref_primary_10_1016_j_heliyon_2024_e25460 crossref_primary_10_1016_j_cger_2020_04_010 crossref_primary_10_1016_j_jlr_2024_100740 crossref_primary_10_1111_bph_15727 crossref_primary_10_1016_j_jare_2021_10_004 crossref_primary_10_3389_fphar_2024_1354809 crossref_primary_10_1080_03639045_2019_1590393 crossref_primary_10_1080_13543776_2024_2332661 crossref_primary_10_1111_eci_13642 crossref_primary_10_1016_j_ajpath_2020_09_011 crossref_primary_10_1016_j_lfs_2023_121505 crossref_primary_10_1007_s00018_023_05061_7 crossref_primary_10_1038_s41575_020_00366_5 crossref_primary_10_1016_j_tem_2024_02_007 crossref_primary_10_1177_0004563218817798 crossref_primary_10_1016_j_phymed_2022_154219 crossref_primary_10_1097_MD_0000000000033981 crossref_primary_10_3390_metabo10110471 crossref_primary_10_3390_ijms22115675 crossref_primary_10_1016_j_disamonth_2023_101592 crossref_primary_10_1016_j_diabet_2018_09_005 crossref_primary_10_1038_s41598_024_51470_4 crossref_primary_10_3390_ijms22168489 crossref_primary_10_4103_jrms_jrms_830_23 crossref_primary_10_1002_mco2_70135 crossref_primary_10_1007_s10620_021_07206_9 crossref_primary_10_1111_apt_16596 crossref_primary_10_1155_2019_8742075 crossref_primary_10_3390_jcm9113409 crossref_primary_10_1042_CS20200446 crossref_primary_10_3390_ijms25084397 crossref_primary_10_1038_s41598_022_10577_2 crossref_primary_10_1016_j_diff_2024_100793 crossref_primary_10_1016_j_phrs_2018_09_025 crossref_primary_10_3350_cmh_2022_0237 crossref_primary_10_3390_nu14020386 crossref_primary_10_1080_13880209_2023_2182892 crossref_primary_10_1016_j_carbpol_2022_120452 crossref_primary_10_1177_20420188211055557 crossref_primary_10_1007_s00018_018_2852_6 crossref_primary_10_1021_acs_analchem_4c03298 crossref_primary_10_3390_jcm8122200 crossref_primary_10_1007_s40519_020_01030_2 crossref_primary_10_1080_17474124_2021_1860019 crossref_primary_10_1016_j_lfs_2020_118986 crossref_primary_10_3389_fmed_2023_1114836 crossref_primary_10_3389_fphar_2024_1327008 crossref_primary_10_3390_diseases6030083 crossref_primary_10_3390_biom8020026 crossref_primary_10_1016_j_bbrc_2020_01_037 crossref_primary_10_12677_ACM_2021_1110694 crossref_primary_10_1590_s2175_97902022e19902 crossref_primary_10_3390_cancers14164051 crossref_primary_10_3390_jcm9113510 crossref_primary_10_1097_MD_0000000000031508 crossref_primary_10_1016_j_phymed_2023_154661 crossref_primary_10_1159_000534284 crossref_primary_10_1038_s41392_022_01070_3 crossref_primary_10_1016_j_metabol_2020_154333 crossref_primary_10_21215_kjfp_2022_12_5_361 crossref_primary_10_1016_j_heliyon_2023_e15146 crossref_primary_10_3390_molecules28248024 crossref_primary_10_3350_cmh_2020_0187 crossref_primary_10_1016_j_cmet_2020_02_014 crossref_primary_10_3390_app10010042 crossref_primary_10_3390_medicines9030020 crossref_primary_10_1155_2019_2943162 crossref_primary_10_1186_s12967_022_03839_0 crossref_primary_10_1155_2022_1786559 crossref_primary_10_3389_fphar_2022_874408 crossref_primary_10_1080_17446651_2019_1571908 crossref_primary_10_1016_j_cellsig_2023_110741 crossref_primary_10_1016_j_metabol_2019_154001 |
| Cites_doi | 10.1111/hepr.12856 10.1016/S0140-6736(15)00803-X 10.1007/s00535-013-0911-1 10.1186/s12876-017-0652-3 10.1002/hep.28431 10.1002/hep.28484 10.1111/apt.13816 10.1111/hepr.12834 10.1111/hepr.12829 10.1002/hep.29302 10.3748/wjg.15.942 10.1046/j.1365-2036.2001.01083.x 10.1016/j.diabet.2015.10.003 10.1001/jama.2008.864 10.1053/j.gastro.2014.06.043 10.1111/jdi.12645 10.1159/000479976 10.1507/endocrj.EJ16-0295 10.1111/liv.12570 10.1111/j.1872-034X.2010.00644.x 10.1002/hep.24544 10.1111/apt.13405 10.1002/hep.29085 10.1136/bmj.c5702 10.1016/j.bioorg.2014.07.003 10.1016/S2213-8587(17)30109-2 10.1002/hep.28785 10.1053/j.gastro.2012.04.001 10.1111/j.1600-065X.2009.00794.x 10.1185/03007995.2014.912983 10.1016/j.cgh.2014.04.038 10.1172/JCI63967 10.1016/j.cgh.2009.05.033 10.1371/journal.pone.0151511 10.3748/wjg.v20.i2.569 10.1002/hep.27647 10.1016/j.ihj.2015.02.007 10.1016/S0168-8278(02)00331-8 10.7326/0003-4819-142-1-200501040-00110 10.1136/annrheumdis-2016-210821 10.1056/NEJMoa1607141 10.1111/dom.12309 10.1053/j.gastro.2017.01.003 10.1007/s00535-012-0653-5 10.1006/bbrc.1999.1403 10.1053/j.gastro.2008.06.047 10.1111/hepr.12351 10.1016/S0140-6736(05)75907-9 10.7326/M15-1774 10.1053/j.gastro.2015.11.048 10.1136/annrheumdis-2015-208029 10.1172/JCI73722 10.2337/dc17-0518 10.1038/srep42477 10.1074/jbc.M112.446575 10.1016/j.atherosclerosis.2016.02.029 10.1016/j.jhep.2017.07.027 10.2169/internalmedicine.8754-16 10.1056/NEJMoa060326 10.1016/j.dld.2007.10.019 10.1002/hep.20092 10.1186/1471-230X-12-2 10.1016/j.jhep.2008.06.018 10.1371/journal.pone.0175717 10.1016/S0168-8278(17)30582-2 10.1136/gutjnl-2015-309265 10.1007/s00535-015-1050-7 10.3109/10715762.2013.837577 10.1016/S0140-6736(14)61933-4 10.1016/j.nut.2014.11.018 10.1007/s00535-010-0291-8 10.1002/hep.20420 10.1007/s11745-001-0824-3 10.1038/srep44754 10.1111/hepr.12793 10.1016/j.nut.2014.08.007 10.1053/j.gastro.2012.10.005 10.1111/liv.13481 10.1016/j.cmet.2013.08.005 10.2337/dc13-2480 10.1053/j.gastro.2016.01.038 10.1053/j.gastro.2014.04.046 10.1111/hepr.12456 10.2337/dc09-0148 10.1111/apt.12352 10.1002/hep.27289 10.1038/nrgastro.2016.3 10.1002/hep.26461 10.1002/hep4.1019 10.1007/s00535-009-0115-x 10.1002/hep.27981 10.1056/NEJMoa0907929 10.1016/j.jhep.2007.04.019 10.1038/nm.3082 10.1016/j.jhep.2013.03.033 10.1002/hep.29514 10.1111/dom.13061 10.1007/s00535-017-1364-8 10.1002/hep.29477 10.1002/hep.29367 10.1111/hepr.12887 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2017 COPYRIGHT 2018 Springer Journal of Gastroenterology is a copyright of Springer, (2017). All Rights Reserved. |
| Copyright_xml | – notice: The Author(s) 2017 – notice: COPYRIGHT 2018 Springer – notice: Journal of Gastroenterology is a copyright of Springer, (2017). All Rights Reserved. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU FYUFA GHDGH H94 K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1007/s00535-017-1415-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central (New) (NC LIVE) url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1435-5922 |
| EndPage | 376 |
| ExternalDocumentID | PMC5847174 A714583396 29247356 10_1007_s00535_017_1415_1 |
| Genre | Journal Article Review |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 2.D 203 28- 29K 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BKNYI BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP D-I DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAS LLZTM M0R M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PCD PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW X7M YLTOR Z45 Z7U Z7W Z82 Z83 Z87 Z8O Z8Q Z8V Z8W Z91 ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY AEIIB PMFND 7T5 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c627t-57a658cce92a2152cb853fc17e30bfe10d41b3319c19608f7da826bb99f93e3e3 |
| IEDL.DBID | 7X7 |
| ISSN | 0944-1174 1435-5922 |
| IngestDate | Thu Aug 21 18:01:47 EDT 2025 Thu Sep 04 22:05:37 EDT 2025 Sat Aug 16 05:43:03 EDT 2025 Tue Jun 17 21:55:19 EDT 2025 Tue Jun 10 20:14:45 EDT 2025 Mon Jul 21 05:58:19 EDT 2025 Tue Jul 01 04:34:15 EDT 2025 Thu Apr 24 23:09:12 EDT 2025 Fri Feb 21 02:29:33 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Hepatic fibrosis Diabetes GLP-1 receptor agonist NASH SGLT2 inhibitor |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c627t-57a658cce92a2152cb853fc17e30bfe10d41b3319c19608f7da826bb99f93e3e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/s00535-017-1415-1 |
| PMID | 29247356 |
| PQID | 1977502604 |
| PQPubID | 33411 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5847174 proquest_miscellaneous_1977784289 proquest_journals_1977502604 gale_infotracmisc_A714583396 gale_infotracacademiconefile_A714583396 pubmed_primary_29247356 crossref_primary_10_1007_s00535_017_1415_1 crossref_citationtrail_10_1007_s00535_017_1415_1 springer_journals_10_1007_s00535_017_1415_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-03-01 |
| PublicationDateYYYYMMDD | 2018-03-01 |
| PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Japan |
| PublicationTitle | Journal of gastroenterology |
| PublicationTitleAbbrev | J Gastroenterol |
| PublicationTitleAlternate | J Gastroenterol |
| PublicationYear | 2018 |
| Publisher | Springer Japan Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Japan – name: Springer – name: Springer Nature B.V |
| References | Marra, Tacke (CR78) 2014; 147 Harrison, Marri, Chalasani (CR82) 2016; 44 Seko, Sumida, Tanaka (CR90) 2015; 45 Loomba, Sirlin, Ang (CR52) 2015; 61 CR39 Watanabe, Hashimoto, Ikejima (CR6) 2015; 50 Mizrahi, Shabat, Ben Ya’acov (CR74) 2012; 5 Kwok, Choi, Wong (CR100) 2016; 65 Sanyal, Chalasani, Kowdley (CR14) 2010; 362 Shah, Lydecker, Murray (CR93) 2009; 7 Seko, Sumida, Tanaka (CR43) 2017; 47 Sumida, Naito, Tanaka (CR16) 2013; 60 Schürks, Glynn, Rist (CR20) 2010; 4 Okajima, Sumida, Taketani (CR98) 2017; 47 Sanyal, Abdelmalek, Suzuki (CR54) 2014; 147 Armstrong, Gaunt, Aithal (CR35) 2016; 387 Ishibashi, Yamashita, Arai (CR57) 2016; 249 Rivera, Adegboyega, van Rooijen (CR75) 2007; 47 CR48 Marso, Bain, Consoli (CR37) 2016; 375 Leeming (CR85) 2017; 66 Staels, Rubenstrunk, Noel (CR30) 2013; 58 Ratziu, Harrison, Francque (CR31) 2016; 150 Miller, Pastor-Barriuso, Dalal (CR18) 2005; 142 Cusi, Orsak, Bril (CR26) 2016; 165 Yoneda, Fujita, Nozaki (CR50) 2010; 40 Imajo, Kessoku, Honda (CR99) 2016; 150 Brenner, Galluzzi, Kepp, Kroemer (CR70) 2013; 59 Sumida, Yoneda, Hyogo (CR94) 2012; 12 Hoofnagle, Van, Kleiner (CR89) 2013; 38 CR53 Sumida, Seko (CR34) 2017; 47 Sumida, Niki, Naito, Yoshikawa (CR10) 2013; 47 Avouac, Konstantinova, Guignabert (CR33) 2017; 76 Weston, Shepherd, Claridge (CR73) 2015; 125 Zein, Yerian, Gogate (CR68) 2011; 54 Mitsuyoshi, Nakashima, Sumida (CR22) 1999; 263 Ruzehaji, Frantz, Ponsoye (CR32) 2016; 75 Chalasani, Younossi, Lavine (CR5) 2012; 142 Scorletti, Bhatia, McCormick (CR55) 2014; 60 McMahan, Wang, Cheng (CR66) 2013; 288 CR67 Honda, Kessoku, Ogawa (CR58) 2017; 7 Ong, Pitts, Younossi (CR105) 2008; 49 Henderson, Sethi (CR81) 2009; 230 Yokohama, Yoneda, Haneda (CR62) 2004; 40 Younossi, Blissett, Blissett (CR107) 2016; 64 DePaoli, Higgins, Henry (CR27) 2014; 37 Seki, Shima, Oya (CR97) 2017; 47 Costabel, Albera, Lancaster, Lin, Hormel, Hulter, Noble (CR87) 2017; 94 Neuschwander-Tetri, Loomba, Sanyal (CR65) 2015; 385 Komiya, Tanaka, Tsuchiya (CR88) 2017; 7 Akuta, Watanabe, Kawamura (CR47) 2017; 1 Nakahara, Hyogo, Yoneda (CR104) 2014; 49 Nakamura, Kamiya, Haneda (CR4) 2017; 8 McPherson, Wilkinson, Tiniakos (CR64) 2017; 12 Aithal, Thomas, Kaye (CR25) 2008; 135 CR79 Younossi, Koenig, Abdelatif (CR1) 2016; 64 Katsiki, Athyros, Karagiannis (CR38) 2017; 5 Yoneda, Yoneda, Mawatari (CR96) 2008; 40 CR71 (CR7) 2016; 64 Doycheva, Cui, Nguyen (CR103) 2016; 43 Hagström, Nasr, Ekstedt (CR76) 2017; 67 Ito, Shimizu, Inoue (CR49) 2017; 40 Dulai, Singh, Patel (CR9) 2017; 65 Komiya, Tsuchiya, Shiba (CR44) 2016; 11 Moon, Finney, Ronnebaum (CR80) 2014; 57 CR8 Belfort, Harrison, Brown (CR24) 2006; 355 Saibara, Onishi, Ogawa (CR28) 1999; 353 Hamaguchi, Takamura, Sakurai (CR92) 2010; 33 Shetty, Kumar, Mathur (CR29) 2015; 67 Gilat, Leikin-Frenkel, Goldiner (CR59) 2001; 36 Gaich, Chien, Fu (CR84) 2013; 18 Yoneda, Hasegawa, Sato (CR13) 2015; 31 Barreyro, Holod, Finocchietto (CR72) 2015; 35 Oza, Eguchi, Mizuta (CR106) 2009; 44 Koehler, Plompen, Schouten (CR102) 2016; 63 Eguchi, Hyogo, Ono (CR2) 2009; 2012 Di Prospero, Artis, Andrade-Gordon (CR77) 2014; 16 Sato, Gosho, Yamamoto (CR15) 2015; 31 Xiao, Zhu, Xiao (CR95) 2017; 66 Park, Shima, Yamaguchi (CR51) 2011; 46 Leiter, Forst, Polidori (CR40) 2016; 42 Takeda, Irahara, Nakano (CR46) 2017; 56 Takase, Nakamura, Miyoshi, Yamamoto, Atsumi (CR45) 2017; 64 Rinella, Sanyal (CR17) 2016; 13 Itoh, Nakayama, Konishi (CR83) 2016; 4 Eguchi, Kitajima, Hyogo (CR36) 2015; 45 Roulot, Roudot-Thoraval (CR101) 2017; 37 Sumida, Nakashima, Yoh (CR11) 2003; 38 Du, Ma, Yu (CR69) 2014; 20 Lippman, Klein, Goodman (CR19) 2009; 301 Singh, Singh, Singh (CR56) 2013; 144 Hasegawa, Yoneda, Nakamura, Makino, Terano (CR12) 2001; 15 Goldberg, Ditah, Saeian (CR3) 2017; 152 Honda, Kessoku, Sumida (CR21) 2017; 17 Lindor, Kowdley, Heathcote (CR23) 2004; 39 Foster (CR61) 2012; 122 Georgescu, Ionescu, Niculescu (CR63) 2009; 15 Safadi, Konikoff, Mahamid (CR60) 2014; 12 Vilar-Gomez, Yasells-Garcia, Martinez-Perez (CR91) 2016; 63 Seino, Sasaki, Fukatsu (CR41) 2014; 30 Shima, Uto, Ueki (CR42) 2013; 48 Reilly, Chiang, Decker (CR86) 2013; 19 E Scorletti (1415_CR55) 2014; 60 D Ito (1415_CR49) 2017; 40 Y Sumida (1415_CR10) 2013; 47 RH McMahan (1415_CR66) 2013; 288 Y Honda (1415_CR21) 2017; 17 Y Sumida (1415_CR94) 2012; 12 D Goldberg (1415_CR3) 2017; 152 E Hamaguchi (1415_CR92) 2010; 33 MJ Armstrong (1415_CR35) 2016; 387 A Okajima (1415_CR98) 2017; 47 K Sato (1415_CR15) 2015; 31 Y Eguchi (1415_CR36) 2015; 45 S McPherson (1415_CR64) 2017; 12 B Staels (1415_CR30) 2013; 58 T Takase (1415_CR45) 2017; 64 FJ Barreyro (1415_CR72) 2015; 35 M Yoneda (1415_CR96) 2008; 40 NC Henderson (1415_CR81) 2009; 230 H Mitsuyoshi (1415_CR22) 1999; 263 Y Honda (1415_CR58) 2017; 7 SA Harrison (1415_CR82) 2016; 44 European Association for the Study of the Liver (EASL) (1415_CR7) 2016; 64 SM Lippman (1415_CR19) 2009; 301 T Saibara (1415_CR28) 1999; 353 C Komiya (1415_CR88) 2017; 7 ZM Younossi (1415_CR107) 2016; 64 N Oza (1415_CR106) 2009; 44 Y Seino (1415_CR41) 2014; 30 EM Koehler (1415_CR102) 2016; 63 LA Leiter (1415_CR40) 2016; 42 1415_CR48 I Doycheva (1415_CR103) 2016; 43 AM DePaoli (1415_CR27) 2014; 37 D Roulot (1415_CR101) 2017; 37 CA Rivera (1415_CR75) 2007; 47 1415_CR8 BA Neuschwander-Tetri (1415_CR65) 2015; 385 N Itoh (1415_CR83) 2016; 4 GP Aithal (1415_CR25) 2008; 135 CO Zein (1415_CR68) 2011; 54 S Watanabe (1415_CR6) 2015; 50 A Takeda (1415_CR46) 2017; 56 Y Seko (1415_CR90) 2015; 45 N Akuta (1415_CR47) 2017; 1 EF Georgescu (1415_CR63) 2009; 15 S Yokohama (1415_CR62) 2004; 40 ZM Younossi (1415_CR1) 2016; 64 1415_CR39 ER Miller 3rd (1415_CR18) 2005; 142 DW Foster (1415_CR61) 2012; 122 T Shima (1415_CR42) 2013; 48 R Loomba (1415_CR52) 2015; 61 M Schürks (1415_CR20) 2010; 4 JH Hoofnagle (1415_CR89) 2013; 38 G Gaich (1415_CR84) 2013; 18 M Yoneda (1415_CR13) 2015; 31 T Nakahara (1415_CR104) 2014; 49 S Ishibashi (1415_CR57) 2016; 249 T Gilat (1415_CR59) 2001; 36 CJ Weston (1415_CR73) 2015; 125 1415_CR67 K Seki (1415_CR97) 2017; 47 N Chalasani (1415_CR5) 2012; 142 U Costabel (1415_CR87) 2017; 94 JP Ong (1415_CR105) 2008; 49 HJ Moon (1415_CR80) 2014; 57 F Marra (1415_CR78) 2014; 147 E Vilar-Gomez (1415_CR91) 2016; 63 1415_CR53 C Brenner (1415_CR70) 2013; 59 N Katsiki (1415_CR38) 2017; 5 V Ratziu (1415_CR31) 2016; 150 Y Seko (1415_CR43) 2017; 47 J Nakamura (1415_CR4) 2017; 8 AJ Sanyal (1415_CR14) 2010; 362 SM Reilly (1415_CR86) 2013; 19 Y Eguchi (1415_CR2) 2009; 2012 S Singh (1415_CR56) 2013; 144 AJ Sanyal (1415_CR54) 2014; 147 J Du (1415_CR69) 2014; 20 R Kwok (1415_CR100) 2016; 65 H Park (1415_CR51) 2011; 46 M Mizrahi (1415_CR74) 2012; 5 KD Lindor (1415_CR23) 2004; 39 G Xiao (1415_CR95) 2017; 66 K Cusi (1415_CR26) 2016; 165 J Avouac (1415_CR33) 2017; 76 NA Prospero Di (1415_CR77) 2014; 16 Y Sumida (1415_CR34) 2017; 47 Y Sumida (1415_CR11) 2003; 38 N Ruzehaji (1415_CR32) 2016; 75 SR Shetty (1415_CR29) 2015; 67 R Safadi (1415_CR60) 2014; 12 R Belfort (1415_CR24) 2006; 355 C Komiya (1415_CR44) 2016; 11 K Imajo (1415_CR99) 2016; 150 ME Rinella (1415_CR17) 2016; 13 AG Shah (1415_CR93) 2009; 7 1415_CR71 Y Sumida (1415_CR16) 2013; 60 M Yoneda (1415_CR50) 2010; 40 T Hasegawa (1415_CR12) 2001; 15 PS Dulai (1415_CR9) 2017; 65 D Leeming (1415_CR85) 2017; 66 1415_CR79 SP Marso (1415_CR37) 2016; 375 H Hagström (1415_CR76) 2017; 67 |
| References_xml | – ident: CR39 – volume: 60 start-page: 1445 year: 2013 end-page: 1450 ident: CR16 article-title: Long-term (≥ 2 year) efficacy of vitamin E for non-alcoholic steatohepatitis publication-title: Hepatogastroenterology – volume: 47 start-page: 266 year: 2017 end-page: 280 ident: CR34 article-title: Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for nonalcoholic fatty liver disease with type 2 diabetes publication-title: Hepatol Res. doi: 10.1111/hepr.12856 – volume: 387 start-page: 679 year: 2016 end-page: 690 ident: CR35 article-title: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study publication-title: Lancet doi: 10.1016/S0140-6736(15)00803-X – volume: 49 start-page: 1477 year: 2014 end-page: 1484 ident: CR104 article-title: Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients publication-title: J Gastroenterol doi: 10.1007/s00535-013-0911-1 – volume: 17 start-page: 96 year: 2017 ident: CR21 article-title: Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study publication-title: BMC Gastroenterol. doi: 10.1186/s12876-017-0652-3 – ident: CR8 – volume: 64 start-page: 73 year: 2016 end-page: 84 ident: CR1 article-title: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology doi: 10.1002/hep.28431 – volume: 63 start-page: 1875 year: 2016 end-page: 1887 ident: CR91 article-title: Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention publication-title: Hepatology doi: 10.1002/hep.28484 – volume: 44 start-page: 1183 year: 2016 ident: CR82 article-title: Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13816 – ident: CR71 – volume: 47 start-page: 1072 year: 2017 end-page: 1078 ident: CR43 article-title: Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus publication-title: Hepatol Res. doi: 10.1111/hepr.12834 – volume: 47 start-page: 882 year: 2017 end-page: 889 ident: CR97 article-title: Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease publication-title: Hepatol Res. doi: 10.1111/hepr.12829 – volume: 66 start-page: 1486 year: 2017 end-page: 1501 ident: CR95 article-title: Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis publication-title: Hepatology. doi: 10.1002/hep.29302 – volume: 15 start-page: 942 year: 2009 end-page: 954 ident: CR63 article-title: Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis publication-title: World J Gastroenterol doi: 10.3748/wjg.15.942 – volume: 15 start-page: 1667 year: 2001 end-page: 1672 ident: CR12 article-title: Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.2001.01083.x – volume: 42 start-page: 25 issue: 1 year: 2016 end-page: 32 ident: CR40 article-title: Effect of canagliflozin on liver function tests in patients with type 2 diabetes publication-title: Diabetes Metab. doi: 10.1016/j.diabet.2015.10.003 – volume: 301 start-page: 39 year: 2009 end-page: 51 ident: CR19 article-title: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT) publication-title: JAMA doi: 10.1001/jama.2008.864 – volume: 147 start-page: 577 issue: 3 year: 2014 end-page: 594 ident: CR78 article-title: Roles for chemokines in liver disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.06.043 – volume: 8 start-page: 397 year: 2017 end-page: 410 ident: CR4 article-title: Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report of the committee on causes of death in diabetes mellitus publication-title: J Diabetes Invest doi: 10.1111/jdi.12645 – volume: 94 start-page: 408 year: 2017 end-page: 415 ident: CR87 article-title: An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP) publication-title: Respiration. doi: 10.1159/000479976 – volume: 64 start-page: 363 year: 2017 end-page: 367 ident: CR45 article-title: Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects publication-title: Endocr J. doi: 10.1507/endocrj.EJ16-0295 – volume: 35 start-page: 953 year: 2015 end-page: 966 ident: CR72 article-title: The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of nonalcoholic steatohepatitis publication-title: Liver Int doi: 10.1111/liv.12570 – volume: 40 start-page: 566 year: 2010 end-page: 573 ident: CR50 article-title: Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study publication-title: Hepatol Res. doi: 10.1111/j.1872-034X.2010.00644.x – volume: 54 start-page: 1610 year: 2011 end-page: 1619 ident: CR68 article-title: Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial publication-title: Hepatology doi: 10.1002/hep.24544 – volume: 4 start-page: 30 year: 2016 ident: CR83 article-title: Roles of FGFs as paracrine or endocrine signals in liver development, health, and disease publication-title: Front Cell Dev Biol. – volume: 43 start-page: 83 year: 2016 end-page: 95 ident: CR103 article-title: Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13405 – volume: 65 start-page: 1557 year: 2017 end-page: 1565 ident: CR9 article-title: Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis publication-title: Hepatology doi: 10.1002/hep.29085 – volume: 4 start-page: c5702 issue: 341 year: 2010 ident: CR20 article-title: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials publication-title: BMJ doi: 10.1136/bmj.c5702 – volume: 57 start-page: 231 year: 2014 end-page: 241 ident: CR80 article-title: Human lysyl oxidase-like 2 publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2014.07.003 – volume: 5 start-page: 329 year: 2017 end-page: 330 ident: CR38 article-title: Semaglutide, lipid-lowering drugs, and NAFLD publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(17)30109-2 – volume: 64 start-page: 1577 year: 2016 end-page: 1586 ident: CR107 article-title: The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe publication-title: Hepatology doi: 10.1002/hep.28785 – volume: 142 start-page: 1592 year: 2012 end-page: 1609 ident: CR5 article-title: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.04.001 – volume: 230 start-page: 160 year: 2009 end-page: 171 ident: CR81 article-title: The regulation of inflammation by galectin-3 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2009.00794.x – volume: 30 start-page: 1245 year: 2014 end-page: 1255 ident: CR41 article-title: Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.912983 – volume: 12 start-page: 2085 year: 2014 end-page: 2091 ident: CR60 article-title: The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.04.038 – volume: 122 start-page: 1958 year: 2012 end-page: 1959 ident: CR61 article-title: Malonyl-CoA: the regulator of fatty acid synthesis and oxidation publication-title: J Clin Invest. doi: 10.1172/JCI63967 – volume: 7 start-page: 1104 year: 2009 end-page: 1112 ident: CR93 article-title: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.05.033 – volume: 11 start-page: e0151511 year: 2016 ident: CR44 article-title: Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction publication-title: PLoS ONE doi: 10.1371/journal.pone.0151511 – volume: 20 start-page: 569 year: 2014 end-page: 577 ident: CR69 article-title: Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i2.569 – volume: 61 start-page: 1239 year: 2015 end-page: 1250 ident: CR52 article-title: Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) publication-title: Hepatology doi: 10.1002/hep.27647 – volume: 67 start-page: 23 year: 2015 end-page: 26 ident: CR29 article-title: Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients publication-title: Indian Heart J doi: 10.1016/j.ihj.2015.02.007 – volume: 38 start-page: 32 year: 2003 end-page: 38 ident: CR11 article-title: Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/S0168-8278(02)00331-8 – volume: 142 start-page: 37 year: 2005 end-page: 46 ident: CR18 article-title: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality publication-title: Ann Intern Med doi: 10.7326/0003-4819-142-1-200501040-00110 – volume: 76 start-page: 1931 year: 2017 end-page: 1940 ident: CR33 article-title: Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension publication-title: Ann Rheum Dis. doi: 10.1136/annrheumdis-2016-210821 – volume: 375 start-page: 1834 year: 2016 end-page: 1844 ident: CR37 article-title: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1607141 – volume: 16 start-page: 1055 year: 2014 end-page: 1064 ident: CR77 article-title: CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study publication-title: Diabetes Obes Metab doi: 10.1111/dom.12309 – volume: 152 start-page: 1090 year: 2017 end-page: 1099 ident: CR3 article-title: Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.01.003 – volume: 48 start-page: 515 year: 2013 end-page: 525 ident: CR42 article-title: Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus publication-title: J Gastroenterol doi: 10.1007/s00535-012-0653-5 – volume: 263 start-page: 537 year: 1999 end-page: 542 ident: CR22 article-title: Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1999.1403 – volume: 135 start-page: 1176 year: 2008 end-page: 1184 ident: CR25 article-title: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.06.047 – volume: 45 start-page: 269 year: 2015 end-page: 278 ident: CR36 article-title: Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J) publication-title: Hepatol Res. doi: 10.1111/hepr.12351 – volume: 2012 start-page: 586 issue: 47 year: 2009 end-page: 595 ident: CR2 article-title: Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study publication-title: J Gastroenterol – volume: 64 start-page: 1388 year: 2016 end-page: 1402 ident: CR7 article-title: EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease publication-title: J Hepatol – volume: 353 start-page: 1802 year: 1999 ident: CR28 article-title: Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis publication-title: Lancet doi: 10.1016/S0140-6736(05)75907-9 – volume: 165 start-page: 305 year: 2016 end-page: 315 ident: CR26 article-title: Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial publication-title: Ann Intern Med doi: 10.7326/M15-1774 – volume: 150 start-page: 626 year: 2016 end-page: 637 ident: CR99 article-title: Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.11.048 – volume: 5 start-page: 141 year: 2012 end-page: 150 ident: CR74 article-title: Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH publication-title: J Inflamm Res. – volume: 75 start-page: 2175 year: 2016 end-page: 2183 ident: CR32 article-title: Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208029 – volume: 125 start-page: 501 year: 2015 end-page: 520 ident: CR73 article-title: Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis publication-title: J Clin Invest. doi: 10.1172/JCI73722 – volume: 40 start-page: 1364 year: 2017 end-page: 1372 ident: CR49 article-title: Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial publication-title: Diabetes Care. doi: 10.2337/dc17-0518 – volume: 7 start-page: 42477 year: 2017 ident: CR58 article-title: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis publication-title: Sci Rep. doi: 10.1038/srep42477 – volume: 288 start-page: 11761 year: 2013 end-page: 11770 ident: CR66 article-title: Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease publication-title: J Biol Chem doi: 10.1074/jbc.M112.446575 – volume: 249 start-page: 36 year: 2016 end-page: 43 ident: CR57 article-title: Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2016.02.029 – volume: 67 start-page: 1265 year: 2017 end-page: 1273 ident: CR76 article-title: Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD publication-title: J Hepatol. doi: 10.1016/j.jhep.2017.07.027 – volume: 56 start-page: 2739 year: 2017 end-page: 2744 ident: CR46 article-title: The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium–glucose cotransporter 2 inhibitor ipragliflozin publication-title: Intern Med. doi: 10.2169/internalmedicine.8754-16 – volume: 355 start-page: 2297 year: 2006 end-page: 2307 ident: CR24 article-title: A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis publication-title: N Engl J Med doi: 10.1056/NEJMoa060326 – ident: CR67 – volume: 40 start-page: 371 year: 2008 end-page: 378 ident: CR96 article-title: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD) publication-title: Dig Liver Dis. doi: 10.1016/j.dld.2007.10.019 – volume: 39 start-page: 770 year: 2004 end-page: 778 ident: CR23 article-title: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial publication-title: Hepatology doi: 10.1002/hep.20092 – volume: 12 start-page: 2 year: 2012 ident: CR94 article-title: Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population publication-title: BMC Gastroenterol. doi: 10.1186/1471-230X-12-2 – volume: 49 start-page: 608 year: 2008 end-page: 612 ident: CR105 article-title: Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2008.06.018 – volume: 12 start-page: e0175717 issue: 4 year: 2017 ident: CR64 article-title: A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis publication-title: PLoS ONE doi: 10.1371/journal.pone.0175717 – volume: 66 start-page: S154 issue: Suppl1 year: 2017 ident: CR85 article-title: Estimation of serum “true collagen type III formation” (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort publication-title: J Hepatol doi: 10.1016/S0168-8278(17)30582-2 – volume: 65 start-page: 1359 year: 2016 end-page: 1368 ident: CR100 article-title: Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study publication-title: Gut doi: 10.1136/gutjnl-2015-309265 – volume: 50 start-page: 364 year: 2015 end-page: 377 ident: CR6 article-title: Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis publication-title: J Gastroenterol doi: 10.1007/s00535-015-1050-7 – volume: 47 start-page: 869 year: 2013 end-page: 880 ident: CR10 article-title: Involvement of free radicals and oxidative stress in NAFLD/NASH publication-title: Free Radic Res. doi: 10.3109/10715762.2013.837577 – volume: 385 start-page: 956 issue: 9972 year: 2015 end-page: 965 ident: CR65 article-title: Farnesoid × nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61933-4 – volume: 31 start-page: 923 year: 2015 end-page: 930 ident: CR15 article-title: Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials publication-title: Nutrition. doi: 10.1016/j.nut.2014.11.018 – volume: 46 start-page: 101 year: 2011 end-page: 107 ident: CR51 article-title: Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease publication-title: J Gastroenterol doi: 10.1007/s00535-010-0291-8 – volume: 40 start-page: 1222 year: 2004 end-page: 1225 ident: CR62 article-title: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.20420 – volume: 36 start-page: 1135 year: 2001 end-page: 1140 ident: CR59 article-title: Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice publication-title: Lipids doi: 10.1007/s11745-001-0824-3 – ident: CR53 – volume: 7 start-page: 44754 year: 2017 ident: CR88 article-title: Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis publication-title: Sci Rep. doi: 10.1038/srep44754 – ident: CR79 – volume: 47 start-page: 721 year: 2017 end-page: 730 ident: CR98 article-title: Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease publication-title: Hepatol Res. doi: 10.1111/hepr.12793 – volume: 31 start-page: 898 year: 2015 end-page: 899 ident: CR13 article-title: Vitamin E therapy for NAFLD/NASH publication-title: Nutrition. doi: 10.1016/j.nut.2014.08.007 – volume: 144 start-page: 323 year: 2013 end-page: 332 ident: CR56 article-title: Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.10.005 – volume: 37 start-page: 1897 year: 2017 end-page: 1906 ident: CR101 article-title: NKontchou G, Kouacou N, Costes JL, Elourimi G, Le Clesiau H, Ziol M, Beaugrand M. Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan publication-title: Liver Int. doi: 10.1111/liv.13481 – ident: CR48 – volume: 18 start-page: 333 year: 2013 end-page: 340 ident: CR84 article-title: The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes publication-title: Cell Metab doi: 10.1016/j.cmet.2013.08.005 – volume: 37 start-page: 1918 year: 2014 end-page: 1923 ident: CR27 article-title: Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? publication-title: Diabetes Care doi: 10.2337/dc13-2480 – volume: 150 start-page: 1147 year: 2016 end-page: 1159 ident: CR31 article-title: Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.01.038 – volume: 147 start-page: 377 year: 2014 end-page: 384 ident: CR54 article-title: No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.04.046 – volume: 45 start-page: E53 year: 2015 end-page: E61 ident: CR90 article-title: Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients publication-title: Hepatol Res. doi: 10.1111/hepr.12456 – volume: 33 start-page: 284 year: 2010 end-page: 286 ident: CR92 article-title: Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis publication-title: Diabetes Care doi: 10.2337/dc09-0148 – volume: 38 start-page: 134 year: 2013 end-page: 143 ident: CR89 article-title: Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12352 – volume: 60 start-page: 1211 year: 2014 end-page: 1221 ident: CR55 article-title: Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study publication-title: Hepatology doi: 10.1002/hep.27289 – volume: 13 start-page: 196 year: 2016 end-page: 205 ident: CR17 article-title: Management of NAFLD: a stage-based approach publication-title: Nat Rev Gastroenterol Hepatol. doi: 10.1038/nrgastro.2016.3 – volume: 58 start-page: 1941 year: 2013 end-page: 1952 ident: CR30 article-title: Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis publication-title: Hepatology doi: 10.1002/hep.26461 – volume: 1 start-page: 46 year: 2017 end-page: 52 ident: CR47 article-title: Effects of a sodium–glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies publication-title: Hepatol Commun. doi: 10.1002/hep4.1019 – volume: 44 start-page: 1203 year: 2009 end-page: 1208 ident: CR106 article-title: A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff publication-title: J Gastroenterol doi: 10.1007/s00535-009-0115-x – volume: 63 start-page: 138 year: 2016 end-page: 147 ident: CR102 article-title: Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study publication-title: Hepatology doi: 10.1002/hep.27981 – volume: 362 start-page: 1675 year: 2010 end-page: 1685 ident: CR14 article-title: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis publication-title: N Engl J Med doi: 10.1056/NEJMoa0907929 – volume: 47 start-page: 571 year: 2007 end-page: 579 ident: CR75 article-title: Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis publication-title: J Hepatol doi: 10.1016/j.jhep.2007.04.019 – volume: 19 start-page: 313 year: 2013 end-page: 321 ident: CR86 article-title: An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice publication-title: Nat Med doi: 10.1038/nm.3082 – volume: 59 start-page: 583 year: 2013 end-page: 594 ident: CR70 article-title: Decoding cell death signals in liver inflammation publication-title: J Hepatol doi: 10.1016/j.jhep.2013.03.033 – volume: 18 start-page: 333 year: 2013 ident: 1415_CR84 publication-title: Cell Metab doi: 10.1016/j.cmet.2013.08.005 – volume: 46 start-page: 101 year: 2011 ident: 1415_CR51 publication-title: J Gastroenterol doi: 10.1007/s00535-010-0291-8 – ident: 1415_CR71 doi: 10.1002/hep.29514 – volume: 152 start-page: 1090 year: 2017 ident: 1415_CR3 publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.01.003 – volume: 67 start-page: 23 year: 2015 ident: 1415_CR29 publication-title: Indian Heart J doi: 10.1016/j.ihj.2015.02.007 – volume: 66 start-page: 1486 year: 2017 ident: 1415_CR95 publication-title: Hepatology. doi: 10.1002/hep.29302 – volume: 43 start-page: 83 year: 2016 ident: 1415_CR103 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13405 – volume: 47 start-page: 721 year: 2017 ident: 1415_CR98 publication-title: Hepatol Res. doi: 10.1111/hepr.12793 – volume: 355 start-page: 2297 year: 2006 ident: 1415_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa060326 – volume: 31 start-page: 923 year: 2015 ident: 1415_CR15 publication-title: Nutrition. doi: 10.1016/j.nut.2014.11.018 – volume: 37 start-page: 1897 year: 2017 ident: 1415_CR101 publication-title: Liver Int. doi: 10.1111/liv.13481 – volume: 263 start-page: 537 year: 1999 ident: 1415_CR22 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1999.1403 – volume: 31 start-page: 898 year: 2015 ident: 1415_CR13 publication-title: Nutrition. doi: 10.1016/j.nut.2014.08.007 – volume: 56 start-page: 2739 year: 2017 ident: 1415_CR46 publication-title: Intern Med. doi: 10.2169/internalmedicine.8754-16 – volume: 40 start-page: 1364 year: 2017 ident: 1415_CR49 publication-title: Diabetes Care. doi: 10.2337/dc17-0518 – volume: 61 start-page: 1239 year: 2015 ident: 1415_CR52 publication-title: Hepatology doi: 10.1002/hep.27647 – volume: 7 start-page: 42477 year: 2017 ident: 1415_CR58 publication-title: Sci Rep. doi: 10.1038/srep42477 – volume: 47 start-page: 869 year: 2013 ident: 1415_CR10 publication-title: Free Radic Res. doi: 10.3109/10715762.2013.837577 – volume: 387 start-page: 679 year: 2016 ident: 1415_CR35 publication-title: Lancet doi: 10.1016/S0140-6736(15)00803-X – volume: 33 start-page: 284 year: 2010 ident: 1415_CR92 publication-title: Diabetes Care doi: 10.2337/dc09-0148 – volume: 362 start-page: 1675 year: 2010 ident: 1415_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa0907929 – volume: 94 start-page: 408 year: 2017 ident: 1415_CR87 publication-title: Respiration. doi: 10.1159/000479976 – volume: 45 start-page: E53 year: 2015 ident: 1415_CR90 publication-title: Hepatol Res. doi: 10.1111/hepr.12456 – volume: 5 start-page: 329 year: 2017 ident: 1415_CR38 publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(17)30109-2 – volume: 35 start-page: 953 year: 2015 ident: 1415_CR72 publication-title: Liver Int doi: 10.1111/liv.12570 – volume: 65 start-page: 1557 year: 2017 ident: 1415_CR9 publication-title: Hepatology doi: 10.1002/hep.29085 – volume: 150 start-page: 1147 year: 2016 ident: 1415_CR31 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.01.038 – volume: 65 start-page: 1359 year: 2016 ident: 1415_CR100 publication-title: Gut doi: 10.1136/gutjnl-2015-309265 – volume: 11 start-page: e0151511 year: 2016 ident: 1415_CR44 publication-title: PLoS ONE doi: 10.1371/journal.pone.0151511 – volume: 12 start-page: 2085 year: 2014 ident: 1415_CR60 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.04.038 – ident: 1415_CR67 – volume: 7 start-page: 1104 year: 2009 ident: 1415_CR93 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2009.05.033 – volume: 135 start-page: 1176 year: 2008 ident: 1415_CR25 publication-title: Gastroenterology doi: 10.1053/j.gastro.2008.06.047 – volume: 353 start-page: 1802 year: 1999 ident: 1415_CR28 publication-title: Lancet doi: 10.1016/S0140-6736(05)75907-9 – volume: 47 start-page: 882 year: 2017 ident: 1415_CR97 publication-title: Hepatol Res. doi: 10.1111/hepr.12829 – volume: 15 start-page: 1667 year: 2001 ident: 1415_CR12 publication-title: Aliment Pharmacol Ther doi: 10.1046/j.1365-2036.2001.01083.x – volume: 45 start-page: 269 year: 2015 ident: 1415_CR36 publication-title: Hepatol Res. doi: 10.1111/hepr.12351 – volume: 7 start-page: 44754 year: 2017 ident: 1415_CR88 publication-title: Sci Rep. doi: 10.1038/srep44754 – volume: 63 start-page: 1875 year: 2016 ident: 1415_CR91 publication-title: Hepatology doi: 10.1002/hep.28484 – volume: 47 start-page: 266 year: 2017 ident: 1415_CR34 publication-title: Hepatol Res. doi: 10.1111/hepr.12856 – volume: 64 start-page: 363 year: 2017 ident: 1415_CR45 publication-title: Endocr J. doi: 10.1507/endocrj.EJ16-0295 – volume: 144 start-page: 323 year: 2013 ident: 1415_CR56 publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.10.005 – volume: 17 start-page: 96 year: 2017 ident: 1415_CR21 publication-title: BMC Gastroenterol. doi: 10.1186/s12876-017-0652-3 – volume: 12 start-page: 2 year: 2012 ident: 1415_CR94 publication-title: BMC Gastroenterol. doi: 10.1186/1471-230X-12-2 – volume: 36 start-page: 1135 year: 2001 ident: 1415_CR59 publication-title: Lipids doi: 10.1007/s11745-001-0824-3 – volume: 48 start-page: 515 year: 2013 ident: 1415_CR42 publication-title: J Gastroenterol doi: 10.1007/s00535-012-0653-5 – volume: 47 start-page: 1072 year: 2017 ident: 1415_CR43 publication-title: Hepatol Res. doi: 10.1111/hepr.12834 – ident: 1415_CR48 doi: 10.1111/dom.13061 – volume: 40 start-page: 1222 year: 2004 ident: 1415_CR62 publication-title: Hepatology doi: 10.1002/hep.20420 – volume: 1 start-page: 46 year: 2017 ident: 1415_CR47 publication-title: Hepatol Commun. doi: 10.1002/hep4.1019 – volume: 2012 start-page: 586 issue: 47 year: 2009 ident: 1415_CR2 publication-title: J Gastroenterol – volume: 142 start-page: 1592 year: 2012 ident: 1415_CR5 publication-title: Gastroenterology doi: 10.1053/j.gastro.2012.04.001 – volume: 60 start-page: 1445 year: 2013 ident: 1415_CR16 publication-title: Hepatogastroenterology – volume: 60 start-page: 1211 year: 2014 ident: 1415_CR55 publication-title: Hepatology doi: 10.1002/hep.27289 – volume: 301 start-page: 39 year: 2009 ident: 1415_CR19 publication-title: JAMA doi: 10.1001/jama.2008.864 – volume: 15 start-page: 942 year: 2009 ident: 1415_CR63 publication-title: World J Gastroenterol doi: 10.3748/wjg.15.942 – volume: 122 start-page: 1958 year: 2012 ident: 1415_CR61 publication-title: J Clin Invest. doi: 10.1172/JCI63967 – volume: 64 start-page: 1388 year: 2016 ident: 1415_CR7 publication-title: J Hepatol – volume: 40 start-page: 566 year: 2010 ident: 1415_CR50 publication-title: Hepatol Res. doi: 10.1111/j.1872-034X.2010.00644.x – volume: 38 start-page: 134 year: 2013 ident: 1415_CR89 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.12352 – volume: 150 start-page: 626 year: 2016 ident: 1415_CR99 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.11.048 – volume: 66 start-page: S154 issue: Suppl1 year: 2017 ident: 1415_CR85 publication-title: J Hepatol doi: 10.1016/S0168-8278(17)30582-2 – volume: 16 start-page: 1055 year: 2014 ident: 1415_CR77 publication-title: Diabetes Obes Metab doi: 10.1111/dom.12309 – volume: 54 start-page: 1610 year: 2011 ident: 1415_CR68 publication-title: Hepatology doi: 10.1002/hep.24544 – volume: 5 start-page: 141 year: 2012 ident: 1415_CR74 publication-title: J Inflamm Res. – volume: 44 start-page: 1203 year: 2009 ident: 1415_CR106 publication-title: J Gastroenterol doi: 10.1007/s00535-009-0115-x – volume: 165 start-page: 305 year: 2016 ident: 1415_CR26 publication-title: Ann Intern Med doi: 10.7326/M15-1774 – volume: 59 start-page: 583 year: 2013 ident: 1415_CR70 publication-title: J Hepatol doi: 10.1016/j.jhep.2013.03.033 – volume: 57 start-page: 231 year: 2014 ident: 1415_CR80 publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2014.07.003 – volume: 47 start-page: 571 year: 2007 ident: 1415_CR75 publication-title: J Hepatol doi: 10.1016/j.jhep.2007.04.019 – volume: 385 start-page: 956 issue: 9972 year: 2015 ident: 1415_CR65 publication-title: Lancet doi: 10.1016/S0140-6736(14)61933-4 – volume: 44 start-page: 1183 year: 2016 ident: 1415_CR82 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13816 – ident: 1415_CR39 doi: 10.1007/s00535-017-1364-8 – volume: 50 start-page: 364 year: 2015 ident: 1415_CR6 publication-title: J Gastroenterol doi: 10.1007/s00535-015-1050-7 – volume: 75 start-page: 2175 year: 2016 ident: 1415_CR32 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208029 – volume: 19 start-page: 313 year: 2013 ident: 1415_CR86 publication-title: Nat Med doi: 10.1038/nm.3082 – volume: 67 start-page: 1265 year: 2017 ident: 1415_CR76 publication-title: J Hepatol. doi: 10.1016/j.jhep.2017.07.027 – volume: 64 start-page: 73 year: 2016 ident: 1415_CR1 publication-title: Hepatology doi: 10.1002/hep.28431 – volume: 76 start-page: 1931 year: 2017 ident: 1415_CR33 publication-title: Ann Rheum Dis. doi: 10.1136/annrheumdis-2016-210821 – volume: 64 start-page: 1577 year: 2016 ident: 1415_CR107 publication-title: Hepatology doi: 10.1002/hep.28785 – ident: 1415_CR79 doi: 10.1002/hep.29477 – volume: 49 start-page: 608 year: 2008 ident: 1415_CR105 publication-title: J Hepatol doi: 10.1016/j.jhep.2008.06.018 – volume: 30 start-page: 1245 year: 2014 ident: 1415_CR41 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.912983 – volume: 58 start-page: 1941 year: 2013 ident: 1415_CR30 publication-title: Hepatology doi: 10.1002/hep.26461 – volume: 375 start-page: 1834 year: 2016 ident: 1415_CR37 publication-title: N Engl J Med doi: 10.1056/NEJMoa1607141 – volume: 12 start-page: e0175717 issue: 4 year: 2017 ident: 1415_CR64 publication-title: PLoS ONE doi: 10.1371/journal.pone.0175717 – volume: 42 start-page: 25 issue: 1 year: 2016 ident: 1415_CR40 publication-title: Diabetes Metab. doi: 10.1016/j.diabet.2015.10.003 – ident: 1415_CR8 doi: 10.1002/hep.29367 – volume: 288 start-page: 11761 year: 2013 ident: 1415_CR66 publication-title: J Biol Chem doi: 10.1074/jbc.M112.446575 – volume: 230 start-page: 160 year: 2009 ident: 1415_CR81 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2009.00794.x – volume: 4 start-page: 30 year: 2016 ident: 1415_CR83 publication-title: Front Cell Dev Biol. – ident: 1415_CR53 doi: 10.1111/hepr.12887 – volume: 39 start-page: 770 year: 2004 ident: 1415_CR23 publication-title: Hepatology doi: 10.1002/hep.20092 – volume: 40 start-page: 371 year: 2008 ident: 1415_CR96 publication-title: Dig Liver Dis. doi: 10.1016/j.dld.2007.10.019 – volume: 249 start-page: 36 year: 2016 ident: 1415_CR57 publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2016.02.029 – volume: 13 start-page: 196 year: 2016 ident: 1415_CR17 publication-title: Nat Rev Gastroenterol Hepatol. doi: 10.1038/nrgastro.2016.3 – volume: 147 start-page: 577 issue: 3 year: 2014 ident: 1415_CR78 publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.06.043 – volume: 147 start-page: 377 year: 2014 ident: 1415_CR54 publication-title: Gastroenterology doi: 10.1053/j.gastro.2014.04.046 – volume: 4 start-page: c5702 issue: 341 year: 2010 ident: 1415_CR20 publication-title: BMJ doi: 10.1136/bmj.c5702 – volume: 37 start-page: 1918 year: 2014 ident: 1415_CR27 publication-title: Diabetes Care doi: 10.2337/dc13-2480 – volume: 63 start-page: 138 year: 2016 ident: 1415_CR102 publication-title: Hepatology doi: 10.1002/hep.27981 – volume: 20 start-page: 569 year: 2014 ident: 1415_CR69 publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i2.569 – volume: 49 start-page: 1477 year: 2014 ident: 1415_CR104 publication-title: J Gastroenterol doi: 10.1007/s00535-013-0911-1 – volume: 8 start-page: 397 year: 2017 ident: 1415_CR4 publication-title: J Diabetes Invest doi: 10.1111/jdi.12645 – volume: 142 start-page: 37 year: 2005 ident: 1415_CR18 publication-title: Ann Intern Med doi: 10.7326/0003-4819-142-1-200501040-00110 – volume: 38 start-page: 32 year: 2003 ident: 1415_CR11 publication-title: J Hepatol doi: 10.1016/S0168-8278(02)00331-8 – volume: 125 start-page: 501 year: 2015 ident: 1415_CR73 publication-title: J Clin Invest. doi: 10.1172/JCI73722 |
| SSID | ssj0013058 |
| Score | 2.6628542 |
| SecondaryResourceType | review_article |
| Snippet | Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 362 |
| SubjectTerms | Abdominal Surgery Agonists Apoptosis Caspase Colorectal Surgery Cysteine Diabetes mellitus Drug Development Endotoxemia Enzyme inhibitors Evidence-based medicine Fatty liver Fenofibrate Fibroblast growth factors Fibrosis Gastroenterology Global Health Health Planning Guidelines Hepatology Humans Intestine Kidneys Lipogenesis Liver Liver diseases Macrolide antibiotics MAP kinase Medical innovations Medicine Medicine & Public Health Molecular Targeted Therapy Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - epidemiology Non-alcoholic Fatty Liver Disease - prevention & control Oxidative stress Pioglitazone Practice Guidelines as Topic Prevalence Review Surgical Oncology TLR4 protein Toll-like receptors Treatment Outcome Type 2 diabetes Vitamin E |
| SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED9GCqMv677nrS0eFAYbyixLsiL6ZNZmYV3zsgS6JyHLMhsrblmTl_71PdmyW4duUPxmnYQ-7nR33N1PAAdSGmeUm5AMzVXCDRcE7eaK8IwnpakSlpa-Gvl0ns2W_NuZOAt13FddtnsXkmxu6r7YrYEiIf5Wpah1CLo8WwL9E5TGrfzrz5Pj2-BB0jzLiY4LJxQt7i6Yed8gA3W0eSnf0UqbGZMbYdNGG013YNGto01C-TNer4qxvd6AeHzgQp_Ck2CdxnnLTs_gkaufw-PTEH9_AYcBzik2dRm3cCTx5S34tT_wuK3oQgc8Rns4nufT70ef5_mP2UtYTo8XX2YkPL9AbJbKFRHSoHlirVOp8a_f2gJVe2WpdCwpKkeTktOCoQhblOJkUsnSoK9SFEpVijn8XsGovqjdG4hZSVnmZMpkIbgRmRH4KZ46iT-YYhEk3SloG7DJ_RMZ57pHVW42ReOmaL8pmkbwse9y2QJz_I_4gz9a7YUWx7Um1B7g7Dz8lc4l9fFjprIIdgeUKGx22Nwxhw7CfqUp2tDCY7PxCN73zb6nT2Cr3cW6pZET9PVUBK9bXuqnnaIPLJnAweWAy3oCDwE-bKl__2qgwH2QGzk8gk8dK92Z1r924-2DqN_BNhqJkzbvbhdGq79rt4eG2KrYD4J3A24bJQA priority: 102 providerName: Springer Nature |
| Title | Current and future pharmacological therapies for NAFLD/NASH |
| URI | https://link.springer.com/article/10.1007/s00535-017-1415-1 https://www.ncbi.nlm.nih.gov/pubmed/29247356 https://www.proquest.com/docview/1977502604 https://www.proquest.com/docview/1977784289 https://pubmed.ncbi.nlm.nih.gov/PMC5847174 |
| Volume | 53 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0DsQX8dvqeVQQBCVc06TNBh-ku-66qFdEXVifSpqmKEh39fb-f2fatHtd8Ci00KQlncxkZjqT3wC8VMo4o92EpWiuMmlkwtBurplMZVSZOhJxRbuRz_N0uZIf18na_3C78GmV_ZrYLtTVxtI_8jOOhkpCAFjy3fYPo6pRFF31JTRuwjFHS4RKN6i12kcRorY-J3owknE0vfuoZtSCiCaC0tYU46jDGB_ppcPV-Yp6OkydPIiftmppcRfueHsyzDoGuAc3XHMfbp37iPkDeOsBmELTVGEHIBJu93DVNEVhtwcLXeYQLdgwzxaf35_l2bflQ1gt5t9nS-YLJjCbxmrHEmXQoLDW6dhQvVpbojKuLVdORGXteFRJXgoUOotyF01qVRn0LspS61oLh8cjOGo2jXsCoai4SJ2KhSoTaZLUJHhoGTuFN4QWAUQ9uQrr0cSpqMXvYsBBbilcIIULonDBA3g9PLLtoDSu6_yK5qAgMcP3WuN3C-DoCLCqyBSniK_QaQAno54oHnbc3M9i4cXzotgzUwAvhmZ6klLOGre57PqoCXpnOoDH3aQPw47Ra1UiwZerETsMHQi0e9zS_PrZgndTWBpZMYA3PeNcGdb_qPH0-o94BrfRjpt0qXEncLT7e-meo620K09bgTiF42wxneZ0_fDj0xyv03n-5Su2ztIZnldx9g_teRI7 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIQEvaHwHBgQJhASyFsd23AghVDGqjrV9YZP65jmOI5BQWlinaf8Uf-Pu8tWlEnub_BY7lnO-893lzr8DeKu19Tb1A5agucqklYqh3Vwwmcgot0Uk4pxuI09nyfhYfp-r-Rb8a-_CUFpleyZWB3W-cPSPfI-joaIIAEt-Wf5hVDWKoqttCY2aLQ79xTm6bKefD_Zxf9_F8ejb0dcxa6oKMJfEesWUtqh1nfNpbKmoq8tQYxWOay-irPA8yiXPBHKmQ-aMBoXOLZrgWZamRSo8Npz3FtyWFGJE-dFzvY5aRFU9UPSYJONo6rdR1KgCLVWC0uQ046gzGe_pwU1tcEUdbqZqbsRrKzU42oH7jf0aDmuGewBbvnwId6ZNhP4RfGoAn0Jb5mENWBIu1_DYxBJhfecLXfQQLeZwNhxN9vdmwx_jx3B8I6R8AtvlovTPIBQ5F4nXsdCZklYlVmFLZew1PhCpCCBqyWVcg15ORTR-mw53uaKwQQoborDhAXzoXlnW0B3XDX5Pe2BIrHFeZ5vbCbg6AsgyQ80pwizSJIDd3kgUR9fvbnfRNMfBqVkzbwBvum56k1LcSr84q8foAXqDaQBP603vlh2jl6yFwsl1jx26AQQS3u8pf_2swMIpDI6sGMDHlnGuLOt_1Hh-_Ue8hrvjo-nETA5mhy_gHtqQgzotbxe2V3_P_Eu001bZq0o4Qji5aWm8BJ4oSIY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3daxQxEB9qheKL-O1qqysoghJus0k2txSRw_O42vYQtHBvaTabRUH2Tnul9F_zr3Nmv657YN9K3jbZkJ3MZGZ2Jr8BeK219Tb1Q5agucqklYqh3Vwwmcgot0Uk4pxuIx_PkumJ_DJX8y34296FobTK9kysDup84egf-YCjoaIIAEsOiiYt4ut48nH5m1EFKYq0tuU0ahY59JcX6L6dfTgY416_iePJ5--fpqypMMBcEusVU9qiBnbOp7GlAq8uQ-1VOK69iLLC8yiXPBPIpQ4ZNRoWOrdojmdZmhap8Nhw3ltwWwspqWyEnut1BCOqaoOi9yQZR7O_jahGFYCpEpQypxlH_cl4TyduaoYrqnEzbXMjdlupxMk9uNvYsuGoZr77sOXLB7Bz3ETrH8J-A_4U2jIPa_CScLmGyib2COv7X-iuh2g9h7PR5Gg8mI2-TR_ByY2Q8jFsl4vSP4VQ5FwkXsdCZ0palViFLZWx1_hApCKAqCWXcQ2SORXU-GU6DOaKwgYpbIjChgfwrntlWcN4XDf4Le2BIRHHeZ1tbirg6ggsy4w0p2izSJMAdnsjUTRdv7vdRdMcDWdmzcgBvOq66U1Kdyv94rweo4foGaYBPKk3vVt2jB6zFgon1z126AYQYHi_p_z5owIOp5A4smIA71vGubKs_1Hj2fUf8RJ2UA7N0cHs8DncQXNyWGfo7cL26s-530OTbZW9qGQjhNObFsZ_N6dMuQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+and+future+pharmacological+therapies+for+NAFLD%2FNASH&rft.jtitle=Journal+of+gastroenterology&rft.au=Sumida%2C+Yoshio&rft.au=Yoneda%2C+Masashi&rft.date=2018-03-01&rft.issn=1435-5922&rft.eissn=1435-5922&rft.volume=53&rft.issue=3&rft.spage=362&rft_id=info:doi/10.1007%2Fs00535-017-1415-1&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0944-1174&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0944-1174&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0944-1174&client=summon |